GlassScriptPhysician profile
Sandra Hlavac
NPI 1679255327
$7,399.78
in general payments reported to CMS, 2019-2025
24 companies · $2,913 in 2025
The $2,913 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,061 · 2024: $3,426 · 2025: $2,913.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,399.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,283.00 | 2023-2025 | |
| Madrigal Pharmaceuticals | $700.52 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $651.12 | 2023-2025 | Dupixent |
| Genzyme Corporation | $582.72 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $534.59 | 2023-2025 | Xifaxan, Trulance |
| Ardelyx, INC. | $432.61 | 2023-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $366.38 | 2023-2025 | Entyvio, Eohilia, Gattex |
| Lilly USA, LLC | $302.33 | 2023-2024 | Omvoh, Mounjaro |
| Phathom Pharmaceuticals, INC. | $257.59 | 2023-2024 | Voquezna |
| Janssen Biotech, INC. | $235.75 | 2024-2025 | Stelara, Tremfya, Simponi Aria |
| Vivus LLC | $234.37 | 2023-2025 | Qsymia, Pancreaze |
| Inspire Medical Systems, INC. | $118.61 | 2025 | Inspire |
| Pfizer INC. | $115.34 | 2024-2025 | |
| Qol Medical, LLC | $83.14 | 2023-2024 | Sucraid, Sucraid |
| Intercept Pharmaceuticals, INC. | $82.17 | 2023-2025 | Ocaliva |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $76.54 | 2025 | Trelegy Ellipta |
| Evoke Pharma, INC. | $75.99 | 2024-2025 | |
| Redhill Biopharma INC. | $64.11 | 2024 | Talicia |
| Celltrion USA INC. | $40.76 | 2025 | Vegzelma |
| Ferring Pharmaceuticals INC. | $37.95 | 2024-2025 | Rebyota |
| Ironwood Pharmaceuticals, INC | $37.85 | 2023-2024 | Linzess |
| Braintree Laboratories, INC. | $32.55 | 2024-2025 | Suflave, Sutab |
| Bayer Healthcare Pharmaceuticals INC. | $32.02 | 2024-2025 | |
| Axonics, INC. | $21.77 | 2024 | Axonics |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Hlavac listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.